文献速递胸部肿瘤

临床I期肺贴壁型腺癌的手术切除范围与淋巴结评估的作用:1991例患者分析

The Role of Extent of Surgical Resection and Lymph Node Assessment for Clinical Stage I Pulmonary Lepidic Adenocarcinoma: An Analysis of 1991 Patients.
PubMed 文献 · J Thorac Oncol · 2017-01-08

基于美国国家癌症数据库1991例临床I期(cT1-2N0M0)贴壁型肺腺癌患者,比较肺叶切除与亚肺叶切除的生存差异。全队列中肺叶切除在单因素及多因素分析中均与生存优势相关,但在仅纳入亚肺叶切除且行淋巴结采样的亚组中,肺叶切除不再独立相关。作者认为应谨慎选择亚肺叶切除,且必须进行充分的病理淋巴结评估。

要点

  • 全队列中肺叶切除较亚肺叶切除与生存优势相关(中位生存9.2年 vs 7.5年,p=0.022)。
  • 亚肺叶切除且行淋巴结采样的亚组中,肺叶切除不再独立相关(HR=0.99,95%CI 0.77-1.27,p=0.905)。
  • 行肺叶切除的患者中6%(n=92)因淋巴结阳性而分期上调,中位采样淋巴结数为7枚(四分位距4-10)。

核心结论

  • 治疗I期贴壁型肺腺癌的外科医生应谨慎使用亚肺叶切除而非肺叶切除,并且必须始终进行充分的病理淋巴结评估。

研究设计与样本

  • 基于美国国家癌症数据库的回顾性分析,纳入1991例临床I期(cT1-2N0M0)贴壁型腺癌且接受肺叶切除或亚肺叶切除的患者。

主要发现

  • 1544例接受肺叶切除,447例接受亚肺叶切除;亚肺叶切除组患者更年长、女性更多、Charlson/Deyo合并症评分更高,但肿瘤更小、T分期更低。
  • 肺叶切除组中6%(n=92)因淋巴结阳性而分期上调,中位采样淋巴结数为7枚(四分位距4-10)。
  • 全队列单因素分析中,肺叶切除较亚肺叶切除与显著生存优势相关(中位生存9.2年 vs 7.5年,p=0.022;5年生存率70.5% vs 67.8%)。
  • 全队列多因素调整后,肺叶切除仍与生存优势相关(HR=0.81,95%CI 0.68-0.95,p=0.011)。
  • 在仅比较亚肺叶切除(含淋巴结采样)与肺叶切除的子集多因素分析中,肺叶切除不再独立与生存改善相关(HR=0.99,95%CI 0.77-1.27,p=0.905)。

临床怎么用

  • 作者认为,治疗I期贴壁型肺腺癌的外科医生应谨慎使用亚肺叶切除而非肺叶切除,并且必须始终进行充分的病理淋巴结评估。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study examined the association of extent of lung resection, pathologic nodal evaluation, and survival for patients with clinical stage I (cT1-2N0M0) adenocarcinoma with lepidic histologic features in the National Cancer Data Base. METHODS: The association between extent of surgical resection and long-term survival for patients in the National Cancer Data Base with clinical stage I lepidic adenocarcinoma who underwent lobectomy or sublobar resection was evaluated using Kaplan-Meier and Cox proportional hazards regression analyses. RESULTS: Of the 1991 patients with cT1-2N0M0 lepidic adenocarcinoma who met the study criteria, 1544 underwent lobectomy and 447 underwent sublobar resection. Patients treated with sublobar resection were older, more likely to be female, and had higher Charlson/Deyo comorbidity scores, but they had smaller tumors and lower T status. Of the patients treated with lobectomy, 6% (n = 92) were upstaged because of positive nodal disease, with a median of seven lymph nodes sampled (interquartile range 4-10). In an analysis of the entire cohort, lobectomy was associated with a significant survival advantage over sublobar resection in univariate analysis (median survival 9.2 versus 7.5 years, p = 0.022, 5-year survival 70.5% versus 67.8%) and after multivariable adjustment (hazard ratio = 0.81, 95% confidence interval: 0.68-0.95, p = 0.011). However, lobectomy was no longer independently associated with improved survival when compared with sublobar resection (hazard ratio = 0.99, 95% confidence interval: 0.77-1.27, p = 0.905) in a multivariable analysis of a subset of patients in which only those patients who had undergone a sublobar resection including lymph node sampling were compared with patients treated with lobectomy. CONCLUSIONS: Surgeons treating patients with stage I lung adenocarcinoma with lepidic features should cautiously utilize sublobar resection rather than lobectomy, and they must always perform adequate pathologic lymph node evaluation.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Cox ML, Yang CJ, Speicher PJ, et al. The Role of Extent of Surgical Resection and Lymph Node Assessment for Clinical Stage I Pulmonary Lepidic Adenocarcinoma: An Analysis of 1991 Patients. J Thorac Oncol. 2017. PMID: 28082103. doi:10.1016/j.jtho.2017.01.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。